The patent protects Orthocell’s intellectual property for the preparation of bioscaffolds and tendon stem cells to treat rotator cuff tears. The intellectual property further protects Orthocell’s novel tendon regeneration technology, known as autologous tenocyte implantation.
More articles on devices:
FDA clears Life Spine’s expandable lateral interbody system
SpineGuard revenue drops 6% in 2014 so far: 10 key concepts
SI-BONE receives 13th patent
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.